Results
| PMID | 19917472 |
| Gene Name | PTGS2 |
| Condition | Endometriosis |
| Association |
Associated |
| Population size | 60 |
| Population details | 60 endometrioses from different sites (ovarian, uterine, and peritoneal) |
| Sex | Female |
| Other associated phenotypes |
Endometriosis |
|
Ann Diagn Pathol. 2009 Dec;13(6):373-7. doi: 10.1016/j.anndiagpath.2009.08.001. Horn, Lars-Christian| Hentschel, Bettina| Meinel, Alexandra| Alexander, Henry| Leo, Cornelia Department of Breast, Gynecologic and Perinatal Pathology, Institute of Pathology, University of Leipzig, D-04103 Leipzig, Germany. hornl@medizin.uni-leipzig.de There is a suggested pathogenetic role of cyclooxygenase-2 (COX-2) in endometriosis via angiogenesis and proproliferative mechanisms. The aim of the study was to investigate the immunohistochemical COX-2 expression in different anatomical sites of endometriosis and its correlation to proliferative activity and periendometriotic vascularization. Sixty endometrioses from different sites (ovarian, uterine, and peritoneal) were evaluated immunohistochemically for COX-2 expression. Cyclooxygenase-2 staining of 75% or more of the cells was defined as COX-2 overexpression and used as cutoff. Proliferative activity was determined by performing Ki-67-labeling index. Periendometriotic vascularization was evaluated by determining microvessel density surrounding the endometriotic focus using CD-34-immunostaining. Cyclooxygenase-2 overexpression was significant more frequent in ovarian endometriosis, when compared with uterine and peritoneal localization (70.8% versus 41.7%; P = .027). There was no significant correlation between COX-2 overexpression and perifocal neovascularization (P = .49). Endometriotic lesions with COX-2 overexpression represented reduced proliferative activity (P = .055). Cyclooxygenase-2 is expressed in the majority of endometriosis, but differences exist within the frequency of overexpression at different anatomical sites of the endometriosis. Cyclooxygenase-2 inhibitors are of clinical interest as treatment options. Mesh Terms: Cell Proliferation| Chi-Square Distribution| Cyclooxygenase 2/*metabolism| Endometriosis/*metabolism/pathology| Female| Humans| Immunohistochemistry| Ki-67 Antigen/*metabolism| Neovascularization, Pathologic/*metabolism| Ovarian Diseases/metaboli |
|